Alkermes(ALKS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In 2025, Alkermes generated total revenues of nearly $1.5 billion, with a year-over-year growth of 9% driven primarily by proprietary products, which generated approximately $1.2 billion in net sales [9][10] - GAAP net income for the year was $241.7 million, with EBITDA of $285.6 million and adjusted EBITDA of $394 million [11] - The company ended the year with $1.3 billion in cash and total investments [12] Business Line Data and Key Metrics Changes - VIVITROL net sales were $467.9 million, ARISTADA net sales were $370 million, and Lybalvi net sales were $346.7 million for 2025 [9][10] - For 2026, total revenues are expected to be in the range of $1.73 billion to $1.84 billion, primarily driven by proprietary products [13] - LUMRYZ, launched in 2023, generated approximately $279 million in net sales in 2025, with expectations of $350 million to $370 million for 2026 [27][30] Market Data and Key Metrics Changes - The company anticipates manufacturing and royalty revenues in the range of $210 million to $240 million for 2026, reflecting the expiration of certain XEPLION royalties [14] - The estimated market for narcolepsy includes about 200,000 patients in the US, with approximately 80,000 currently being treated [63] Company Strategy and Development Direction - The acquisition of Avadel is seen as a strategic step to enter the commercial sleep medicine market and enhance the company's product portfolio [6][12] - The company plans to advance its orexin portfolio, including alixorexton, which is expected to enter Phase 3 trials for narcolepsy [7][31] - The focus remains on operational discipline, efficient capital allocation, and investing in long-term growth opportunities [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position and the potential for growth in 2026, despite anticipated GAAP net losses due to accounting related to the Avadel acquisition [17] - The company is committed to delivering shareholder growth and maintaining a strong cash flow positive profile [20][21] Other Important Information - The transition of CEO from Richard Pops to Blair Jackson is planned for summer 2026, with Pops continuing as chairman [38] - The company is focused on integrating the Avadel team and leveraging their expertise in sleep medicine [29] Q&A Session Summary Question: Phase 3 trial design and AE profile - Management indicated that the orexin 2 receptor agonists have a favorable AE profile and that split dosing is designed to maximize efficacy while minimizing side effects [42][43] Question: Potential synergies across sales forces - The integration of the Avadel commercial team is expected to enhance the company's presence in sleep medicine, with no immediate overlap with the psychiatry sales force [45][46] Question: Evidence needed for payer reimbursement for both drugs - Management believes that both orexin agonists and oxybates will serve different patient needs, and data will be generated to support reimbursement for both [48][49] Question: Internal bar for ESS in LUMRYZ phase 3 - Management expects the data from the IH study to mirror previous successful programs, with key secondaries being important for prescriber confidence [54][58] Question: Current understanding of NT1 vs NT2 and IH dynamics - The company acknowledges a significant unmet need in the IH market and plans to wait for phase 2 data before initiating phase 3 discussions with the FDA [60][63] Question: Plans to study LUMRYZ with oxybate - Management sees potential benefits for patients using both treatments and plans to build evidence for reimbursement purposes [67][69] Question: Field force strategy for LUMRYZ - The current sales force is deemed right-sized to target the oxybate-eligible patient segment, with ongoing monitoring of market dynamics [72][74] Question: SG&A spend beyond 2026 - Management indicated that one-time transaction costs will not carry over, and future spending will be controlled with potential synergies from the Avadel acquisition [76][78]